...
首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >Relationships between the catechol substrate binding site and amphetamine, cocaine, and mazindol binding sites in a kinetic model of the striatal transporter of dopamine in vitro.
【24h】

Relationships between the catechol substrate binding site and amphetamine, cocaine, and mazindol binding sites in a kinetic model of the striatal transporter of dopamine in vitro.

机译:在体外多巴胺的纹状体转运蛋白动力学模型中,邻苯二酚底物结合位点与苯丙胺,可卡因和mazindol结合位点之间的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Experiments were conducted to determine how (-)-cocaine and S(+)-amphetamine binding sites relate to each other and to the catechol substrate site on the striatal dopamine transporter (sDAT). In controls, m-tyramine and S(+)-amphetamine caused release of dopamine from intracellular stores at concentrations > or = 12-fold those observed to inhibit inwardly directed sDAT activity for dopamine. In preparations from animals pretreated with reserpine, m-tyramine and S(+)-amphetamine caused release of preloaded dopamine at concentrations similar to those that inhibit inwardly directed sDAT activity. S(+)-Amphetamine and m-tyramine inhibited sDAT activity for dopamine by competing for a common binding site with dopamine and each other, suggesting that phenethylamines are substrate analogues at the plasmalemmal sDAT. (-)-Cocaine inhibited sDAT at a site separate from that for substrate analogues. This site is mutually interactive with the substrate site (K(int) = 583 nM). Mazindol competitively inhibited sDAT at the substrate analogue binding site. The results with (-)-cocaine suggest that the (-)-cocaine binding site on sDAT is distinct from that of hydroxyphenethylamine substrates, reinforcing the notion that an antagonist for (-)-cocaine binding may be developed to block (-)-cocaine binding with minimal effects on dopamine transporter activity. However, a strategy of how to antagonize drugs of abuse acting as substrate analogues is still elusive.
机译:进行实验以确定(-)-可卡因和S(+)-苯异丙胺结合位点如何相互关联以及与纹状体多巴胺转运蛋白(sDAT)上的邻苯二酚底物位点如何相关。在对照中,间酪胺和S(+)-苯丙胺导致多巴胺以大于或等于观察到的抑制多巴胺向内定向的sDAT活性的浓度的12倍从细胞内存储释放。在利血平预处理动物的制剂中,间酪胺和S(+)-苯丙胺导致预加载的多巴胺释放,其浓度类似于抑制向内定向的sDAT活性的浓度。 S(+)-苯丙胺和间苯丙胺通过与多巴胺相互竞争共同的结合位点而抑制了多巴胺的sDAT活性,这表明苯乙胺是血浆中sDAT的底物类似物。 (-)-可卡因在与底物类似物不同的位点抑制sDAT。该位点与底物位点相互相互作用(K(int)= 583 nM)。 Mazindol在底物类似物结合位点竞争性抑制sDAT。 (-)-可卡因的结果表明sDAT上的(-)-可卡因结合位点与羟苯乙胺底物的结合位点不同,这强化了这样一种观念,即可以开发出(-)-可卡因结合的拮抗剂来阻断(-)-可卡因结合对多巴胺转运蛋白活性影响最小。然而,如何对抗作为底物类似物的滥用药物的策略仍然难以捉摸。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号